
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is supported by a powerful China recovery, with 2Q’26 net sales of $93.5M rising 111% year over year and China revenue of $52.3M growing over 100% on continued EVO+ adoption, while ex-China sales still increased 6% despite Middle East-related EMEA softness. Profitability is also inflecting sharply, as adjusted EBITDA reached $20.0M with a 21.4% margin versus a loss in 2Q’25, helped by 74.5% gross margin, disciplined operating expense management, and a clean liquidity position of $181.5M in cash and investments with no debt. The leadership transition to permanent CEO Warren Foust further reduces uncertainty, and management’s confidence around demand outstripping supply, no distributor inventory build, and eventual normalization of tariff drag supports a constructive long-term outlook.
Bears say
Staar Surgical is facing a deteriorating competitive position in China as EyeBright’s domestically manufactured phakic lens launched in spring 2025 at roughly one-third the cost of STAA’s ICL, with clinicians viewing early quality as comparable and suggesting meaningful share loss once 6-12 months of follow-up data accumulates. The company’s core ICL franchise is also constrained by a cautious adoption cycle in young patients, where long-term biocompatibility data is essential, while one expert estimated EyeBright could take 10%-15% of the China ICL market near term and potentially 40% in coming years if results hold. More broadly, the addressable market appears structurally limited because LASIK remains the dominant refractive procedure due to lower cost, bilateral same-day treatment, and surgeon economics, leaving ICL as a niche option for patients who cannot undergo LASIK or PRK.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About STAAR Surgical (STAA) Forecast
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares